Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Randomized, Single-dose, Crossover, 2-Period, Open-Label Study to Assess the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants

NCT07723833 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07723833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07723833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Randomized, Single-dose, Crossover, 2-Period, Open-Label Study to Assess the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Recruiting
Start date
July 27, 2026
Completion date
November 18, 2026
Enrollment
152 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants